LifeMD, Inc. (NASDAQ:LFMD) Receives Consensus Rating of “Moderate Buy” from Brokerages

LifeMD, Inc. (NASDAQ:LFMD) has earned a consensus rating of “Moderate Buy” from the ten analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $9.1429.

LFMD has been the topic of several recent analyst reports. Mizuho upgraded shares of LifeMD from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $6.00 to $8.00 in a report on Monday, March 16th. Weiss Ratings upgraded shares of LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a report on Thursday, May 7th. Loop Capital set a $10.00 price objective on shares of LifeMD in a report on Thursday, March 12th. UBS Group restated a “buy” rating on shares of LifeMD in a report on Wednesday, May 27th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of LifeMD in a report on Tuesday, March 10th.

Hedge Funds Weigh In On LifeMD

Hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC increased its holdings in shares of LifeMD by 110.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock valued at $64,000 after acquiring an additional 2,452 shares in the last quarter. Quarry LP acquired a new position in LifeMD in the 3rd quarter worth approximately $52,000. Legal & General Group Plc increased its holdings in LifeMD by 187.4% in the 2nd quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock worth $138,000 after buying an additional 6,614 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in LifeMD in the 4th quarter worth approximately $36,000. Finally, Hudson Bay Capital Management LP acquired a new position in LifeMD in the 2nd quarter worth approximately $153,000. Institutional investors and hedge funds own 35.52% of the company’s stock.

LifeMD Stock Performance

Shares of LifeMD stock opened at $4.50 on Thursday. The company has a market capitalization of $217.62 million, a PE ratio of 90.02 and a beta of 1.98. The company has a 50-day simple moving average of $4.55 and a two-hundred day simple moving average of $3.85. LifeMD has a one year low of $2.56 and a one year high of $14.43.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.06). LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%. The company had revenue of $50.16 million for the quarter, compared to analyst estimates of $48.84 million. On average, equities analysts predict that LifeMD will post -0.37 earnings per share for the current fiscal year.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.